These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34535355)

  • 1. Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment.
    Spek A; Graser A; Casuscelli J; Szabados B; Rodler S; Marcon J; Stief C; Staehler M
    Urol Oncol; 2022 Jan; 40(1):13.e1-13.e8. PubMed ID: 34535355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
    Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
    Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
    Williams R; Hudson JM; Lloyd BA; Sureshkumar AR; Lueck G; Milot L; Atri M; Bjarnason GA; Burns PN
    Radiology; 2011 Aug; 260(2):581-90. PubMed ID: 21555352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.
    Hellbach K; Sterzik A; Sommer W; Karpitschka M; Hummel N; Casuscelli J; Ingrisch M; Schlemmer M; Graser A; Staehler M
    Eur Radiol; 2017 Jun; 27(6):2532-2537. PubMed ID: 27678131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
    Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
    Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
    Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
    Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.
    Hudson JM; Williams R; Karshafian R; Milot L; Atri M; Burns PN; Bjarnason GA
    Invest Radiol; 2014 Feb; 49(2):116-23. PubMed ID: 24220251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
    Han KS; Jung DC; Choi HJ; Jeong MS; Cho KS; Joung JY; Seo HK; Lee KH; Chung J
    Cancer; 2010 May; 116(10):2332-42. PubMed ID: 20225226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.
    Ladoire S; Bonnetain F; Gauthier M; Zanetta S; Petit JM; Guiu S; Kermarrec I; Mourey E; Michel F; Krause D; Hillon P; Cormier L; Ghiringhelli F; Guiu B
    Oncologist; 2011; 16(1):71-81. PubMed ID: 21212435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma.
    Drljevic-Nielsen A; Rasmussen F; Nielsen PS; Stilling C; Thorup K; Mains JR; Madsen HHT; Donskov F
    Eur Radiol Exp; 2021 Jul; 5(1):32. PubMed ID: 34327591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
    Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
    Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.
    Panebianco V; Iacovelli R; Barchetti F; Altavilla A; Forte V; Sciarra A; Cortesi E; Catalano C
    Anticancer Res; 2013 Dec; 33(12):5663-6. PubMed ID: 24324114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.